Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MIN-117

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
MIN-117
Clinical data
Other namesWF-516
Identifiers
  • (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol[1]
CAS Number
PubChemCID
ChemSpider
UNII
Chemical and physical data
FormulaC25H25Cl2N3O
Molar mass454.40 g·mol−1
3D model (JSmol)
  • CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O
  • InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1
  • Key:XIYDIPLATGRHEC-SFHVURJKSA-N

MIN-117 (known formerly asWF-516) is an investigationalantidepressant which is under development byMinerva Neurosciences for the clinical treatment ofmajor depressive disorder (MDD).[2][3][4] It is described as a5-HT1A and5-HT2A receptorantagonist andinhibitor ofserotonin anddopaminereuptake,[4][5][6] and is also reported to possessaffinity for theα1A- andα1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is inphase IIclinical trials for MDD.[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.[7]

See also

[edit]

References

[edit]
  1. ^Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. (2012)."Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain".PLOS ONE.7 (8) e42589.Bibcode:2012PLoSO...742589S.doi:10.1371/journal.pone.0042589.PMC 3413639.PMID 22880045.
  2. ^"Minerva Neuroscience". Retrieved2015-05-19.
  3. ^abMinerva Neurosciences (2015)."Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved2015-05-19.
  4. ^abcMinerva Neurosciences."Investor Presentation March 2015"(PDF). Archived fromthe original(PDF) on 2015-05-20. Retrieved2015-05-19.
  5. ^"Company Profile for Minerva Neurosciences Inc". Reuters. Archived fromthe original on 2015-05-20. Retrieved2015-05-19.
  6. ^abDion D (2014)."Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved2015-05-19.
  7. ^"Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder".BioSpace. Retrieved2020-07-28.

External links

[edit]
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MIN-117&oldid=1314202903"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp